Hims & Hers Health and Novo Nordisk both saw their shares drop after reporting strong growth, as investors focused on rising costs in the weight-loss pill market. Hims & Hers posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected, and raised its full-year revenue outlook to $3.1 billion to $3.3 billion, but swung to a $127.9 million net loss from a $43.5 million profit a year earlier. Novo Nordisk raised its annual guidance to a range of adjusted sales and operating profit down 6% to flat, versus a prior range of down 4% to 12%, yet its Wegovy pill sales of 3.22 billion kroner missed the 3.33 billion kroner analysts expected. Hims & Hers shares fell over 2% on Tuesday, while Novo Nordisk shares dropped about 6% a week earlier.
Novo Nordisk A/SRaised guidance but Wegovy sales missed expectations, causing shares to fall.
AstraZeneca PLC
Hims Hers Health IncRevenue beat and raised guidance but swung to a net loss, driving shares down.
